Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis

Cheevers, William P.; Snekvik, Kevin; Trujillo, Jessie D.; Kumpula-McWhirter, Nancy; Top, K.J Pretty On; Knowles, Donald P.

doi:10.1016/s0042-6822(02)00044-2

Cited by 32 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent vaccination studies in goats and sheep have shown that env immunization can induce lower virus loads or disease [12] and [19]. Significant differences between these studies and the present work exist.…”

Section: Discussioncontrasting

confidence: 66%

“…However, recently it has been shown that immunization of goats with recombinant gp135 glycoprotein of CAEV induces neutralizing antibodies [11], suggesting that protective effects may be possible. Indeed, the use of plasmid DNA vaccination or live viral vectors encoding CAEV env gene has demonstrated that reductions in virus load and disease can be achieved [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes

Niesalla

Andrés

Barbezange

et al. 2009

Vaccine

View full text Add to dashboard Cite

To determine whether systemic immunization with plasmid DNA and virus vector against visna/maedi virus (VMV) would induce protective immune responses, sheep were immunized with VMV gag and/or env sequences using particle--mediated epidermal bombardment and injection of recombinant modified vaccinia Ankara. The results showed that immunization induced both humoral and cell--mediated responses prior to and after virus challenge. The vaccination protocol did not prevent infection, but immunization with the gag gene or a combination of gag and env genes resulted in significantly reduced provirus loads in blood and mediastinal lymph node, respectively. Provirus loads in lung and draining lymph node were unaffected, but p25 expression was undetectable in lungs of animals immunized with a combination of gag and env genes. Analysis of target tissues for lesions at post--mortem showed that immunization with the env gene caused a significant increase in lesion score, while the gag gene or a combination of gag and env genes had no effect. Inclusion of the ovine interferon--γ gene in the initial priming mixture had minimal effect on immune responses, provirus load, or lesion development, although it resulted in a decreased p25 expression in the lung. The results thus show that systemic immunization with gag or a combination of gag and env genes reduces provirus load in blood and lymphoid tissue, respectively whereas env immunization has no effect on provirus load but increased lesion development.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes

Niesalla

Andrés

Barbezange

et al. 2009

Vaccine

View full text Add to dashboard Cite

show abstract

“…So far no one has been able to show whether T cells are protective against MVV infection (17,18). Similar vaccination attempts against the small-ruminant lentiviruses (MVV and CAEV) have been unsuccessful at producing sterile immunity (10,11,13,22,37,41,46,53) and often make the pathology seen after infection worse (37,41,53). Indeed, CD4…”

Section: Discussionmentioning

confidence: 99%

Immune Response to Individual Maedi-Visna VirusgagAntigens

Singh

McConnell

Blacklaws

2006

J Virol

View full text Add to dashboard Cite

The lesions caused by maedi-visna virus (MVV) are known to be immune mediated with a presumed contribution by the response to viral antigens. However, very little is known about the T-cell response to individual viral proteins. We have therefore expressed the three individual gag antigens of MVV strain EV1 (p16, p25, and p14) in a bacterial expression system and used the purified recombinant proteins to analyze the antibody and CD4؉ T-cell response to MVV. Plasma samples were taken from sheep after 1 year of infection with MVV. The titers for antibodies in these samples were determined by indirect enzyme-linked immunosorbent assays and were as follows: anti-p25 antibody, 1:400 to >1:3,200; anti-p16 antibody, 1:400 to 1:3,200; and anti-p14 antibody, 1:<100 to 1:3,200. When the induction of antibodies was followed over time postinfection (p.i.), samples positive for anti-p25 were seen by day 24 p.i., followed by anti-p16 by day 45 p.i., and lastly anti-p14 by day 100 p.i. T-cell proliferative responses to all three gag antigens were detected in persistently infected sheep peripheral blood lymphocytes. The antigens were therefore used to raise T-cell lines from persistently infected sheep. These T-cell lines were shown to be specific for the recombinant gag antigens and for viral antigen expressed on infected macrophages. The proliferative response was restricted to major histocompatibility complex class II HLA-DR and so was due to CD4 ؉ T lymphocytes. All three gag antigens may therefore play a role in immune-mediated lesion formation in MVV disease by presentation on infected macrophages in lesions.

show abstract

“…Another means of improving DNA vaccines is to combine them with inactivated virus or purified protein in a DNA prime-protein boost protocol. Several recent studies involving plasmids encoding one or more viral proteins as an initial vaccine followed by a boost with inactivated virus [83] or purified protein [90] have demonstrated significant enhancement of immune responses. These results indicate that DNA priming followed by a boost with purified recombinant protein is a reasonable strategy to pursue in developing an effective vaccine against OvHV-2.…”

Section: Dna Vaccinesmentioning

confidence: 99%

Sheep-associated malignant catarrhal fever virus: prospects for vaccine development

Taus

Oaks

2006

Expert Review of Vaccines

View full text Add to dashboard Cite

Sheep-associated malignant catarrhal fever is emerging as a significant problem for several ruminant species worldwide. The inability to propagate the causative agent, ovine herpesvirus 2, in vitro has seriously hindered research efforts in the development of effective programs for control of the disease in clinically susceptible hosts. Recent molecular technologic advances have provided powerful tools for investigating this difficult-to-study virus. Identification of the infectious virus source, establishment of experimental animal models and completion of sequencing the genome for ovine herpesvirus 2 have put us in a position to pursue the development of vaccines for control of the disease. In this review, the authors briefly describe the current understanding of ovine herpesvirus 2 and prospectively discuss vaccine development against the virus.

show abstract

Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis

Cited by 32 publications

References 30 publications

Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes

Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes

Immune Response to Individual Maedi-Visna VirusgagAntigens

Sheep-associated malignant catarrhal fever virus: prospects for vaccine development

Contact Info

Product

Resources

About